bluebird bio, Inc. (NASDAQ:BLUE - Free Report) - William Blair issued their Q1 2025 earnings per share (EPS) estimates for bluebird bio in a research note issued on Tuesday, March 26th. William Blair analyst S. Corwin expects that the biotechnology company will earn ($0.46) per share for the quarter. William Blair currently has a "Market Perform" rating on the stock. The consensus estimate for bluebird bio's current full-year earnings is ($1.78) per share. William Blair also issued estimates for bluebird bio's Q2 2025 earnings at ($0.34) EPS.
Other equities analysts have also recently issued research reports about the company. Royal Bank of Canada reissued a "sector perform" rating and issued a $6.00 price target on shares of bluebird bio in a research note on Wednesday. Wells Fargo & Company reduced their target price on bluebird bio from $4.00 to $3.00 and set an "equal weight" rating for the company in a report on Wednesday. Wedbush dropped their price target on bluebird bio from $1.72 to $1.68 and set a "neutral" rating on the stock in a research report on Tuesday, March 19th. StockNews.com raised bluebird bio to a "sell" rating in a research note on Friday, December 8th. Finally, Morgan Stanley raised shares of bluebird bio from an "underweight" rating to an "equal weight" rating and increased their price target for the stock from $3.00 to $7.00 in a research report on Friday, December 8th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $5.87.
Check Out Our Latest Analysis on BLUE
bluebird bio Price Performance
Shares of NASDAQ:BLUE traded down $0.08 on Thursday, reaching $1.28. 7,253,083 shares of the company traded hands, compared to its average volume of 9,900,090. The stock has a market capitalization of $139.96 million, a PE ratio of -1.73 and a beta of 0.75. The company's 50 day moving average is $1.24 and its 200-day moving average is $2.27. bluebird bio has a fifty-two week low of $0.88 and a fifty-two week high of $5.53.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company boosted its holdings in bluebird bio by 6.2% in the 4th quarter. The Manufacturers Life Insurance Company now owns 31,773 shares of the biotechnology company's stock valued at $220,000 after purchasing an additional 1,862 shares during the period. Mariner LLC raised its holdings in bluebird bio by 12.8% in the 4th quarter. Mariner LLC now owns 17,972 shares of the biotechnology company's stock valued at $124,000 after acquiring an additional 2,043 shares in the last quarter. American International Group Inc. grew its holdings in shares of bluebird bio by 7.1% during the 4th quarter. American International Group Inc. now owns 39,274 shares of the biotechnology company's stock worth $272,000 after purchasing an additional 2,609 shares in the last quarter. Captrust Financial Advisors raised its stake in shares of bluebird bio by 22.5% in the third quarter. Captrust Financial Advisors now owns 14,679 shares of the biotechnology company's stock valued at $93,000 after purchasing an additional 2,700 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in bluebird bio by 15.5% during the second quarter. Tower Research Capital LLC TRC now owns 23,160 shares of the biotechnology company's stock worth $76,000 after buying an additional 3,104 shares in the last quarter. 87.43% of the stock is owned by institutional investors.
bluebird bio Company Profile
(
Get Free Report)
bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.
Recommended Stories
Before you consider bluebird bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and bluebird bio wasn't on the list.
While bluebird bio currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
